Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) and Neoleukin Therapeutics (NASDAQ:NLTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Volatility and Risk
Tonix Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
Profitability
This table compares Tonix Pharmaceuticals and Neoleukin Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tonix Pharmaceuticals | -1,197.86% | -163.95% | -118.88% |
| Neoleukin Therapeutics | N/A | -37.22% | -30.91% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tonix Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| Neoleukin Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Tonix Pharmaceuticals presently has a consensus target price of $53.50, suggesting a potential upside of 23,457.90%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than Neoleukin Therapeutics.
Institutional & Insider Ownership
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Tonix Pharmaceuticals and Neoleukin Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tonix Pharmaceuticals | $11.29 million | 3.76 | -$116.66 million | ($52.74) | 0.00 |
| Neoleukin Therapeutics | N/A | N/A | -$57.56 million | ($3.11) | -6.30 |
Neoleukin Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Tonix Pharmaceuticals beats Neoleukin Therapeutics on 7 of the 13 factors compared between the two stocks.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
